Three years after severe COVID-19 hospitalization, significant risks of mortality and long-term symptoms persist, impacting overall health and quality of life.
FDA approves Taiho’s Lonsurf with bevacizumab for metastatic colorectal cancer
The FDA on Wednesday approved Taiho Oncology’s Lonsurf (trifluridine and tipiracil) with bevacizumab for metastatic colorectal cancer (mCRC) in those who were previously treated with
August 3, 2023